N	Concordance
1	mation on  plasmacytoma and plasma cell myeloma, and on the management of lymph
2	venously with fresh bone-marrow-derived myeloma cells, including monoclonal gamm
3	 rare) of patients with newly diagnosed myeloma. Treatment is usually continued 
4	al blood after stem cell transplant for myeloma shows disparate tumor involvemen
5	lesions in mice characteristic of human myeloma bone disease. The cell line prod
6	 evident in the escape phase of an IgA1 myeloma patient treated with interferon 
7	ld be confirmed by the uptake of an IgE myeloma protein coupled to colloidal gol
8	expression of CD95 induced apoptosis in myeloma cell lines in a manner dependent
9	ugh important predictors of survival in myeloma patients have been identified, i
10	cell lines and in many freshly isolated myeloma cells. However, some of the latt
11	igh  risk of relapse, advanced multiple myeloma, or advanced ovarian cancer    
12	  es. Indolent or asymptomatic multiple myeloma accounts for approximately 20&#3
13	oma and possibly also in human multiple myeloma is to ensure abnormal survival a
14	py for patients with recurrent multiple myeloma after an  allogeneic marrow tran
15	gh-dose therapy for refractory multiple myeloma: improved prognosis with better 
16	type of CIDP occurs with osteosclerotic myeloma and monoclonal IgG or IgA antibo
17	pear.  Patients with MGUS or smoldering myeloma do not respond more  frequently,
18	Since the great majority of symptomatic myeloma patients are classified as stag
19	n a patient with anemia associated with myeloma should be based on pretreatment